Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
作者: Perrine CréquitAnna ChaimaniAmélie YavchitzNassima AtticheJacques CadranelLudovic TrinquartPhilippe Ravaud
作者单位: 1Centre de Recherche Epidémiologie et Statistique Paris Sorbonne Cité, INSERM U1153
2Université Paris Descartes – Sorbonne Paris cité
3Centre d’Epidémiologie Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Hôtel-Dieu
4Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon
5Cochrane France
6Centre d’Epidémiologie Clinique, Hôpital Hôtel-Dieu
7Service d’Anesthésie-Réanimation, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris
8Sorbonne Universités, UPMC Univ.
9Boston University School of
刊名: BMC Medicine, 2017, Vol.15 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s12916-017-0954-x
关键词: Systematic reviewComparative effectiveness reviewNSCLCImmunotherapyTreatmentsWild-type EGFR
英文摘要: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on this topic is increasing. Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis.
原始语种摘要: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on this topic is increasing. Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:6.679 (2012)

×
关键词翻译
关键词翻译
  • epidermal 上皮的
  • review 复审
  • status 状态
  • efficacy 效验
  • unknown 不知道的
  • systematic 有系统的
  • cancer 癌症
  • comparative 比较的
  • factor 因素
  • growth 生长